Cipla, eyeing growth from the international market, is planning to launch at least one product in the United States every year
A prominent name in the respiratory segment in India, Cipla, has added $70-100 million in revenues last financial year. A Business Standard report said the company now aims to launch at least one product in the US every year from next year.
Cipla Chief Executive Officer (CEO) Umang Vohra was quoted as saying that the firm was planning to work closely with diagnostic centres to boost the detection rates of respiratory illnesses.
He added: “There are an estimated 90 million patients with respiratory illnesses in India of whom only 30 million are diagnosed. Less than 10 million actually get proper treatment.”
Image Credit : cipla.com